2022年3月26日 · We conducted two randomized, placebo-controlled, phase 3 trials (BRAVE-AA1 and BRAVE-AA2) involving adults with severe alopecia areata with a Severity of Alopecia Tool (SALT) score of 50 or...

Baricitinib, an oral, reversible, selective JAK1/JAK2 inhibitor, was shown to be superior to placebo on hair growth after 36 weeks of treatment in adults with severe AA in a phase 2 trial and recently in two phase 3 trials (BRAVE-AA1 and BRAVE-AA2).

Baricitinib an orally administered, selective JAK1 and JAK2 inhibitor is a promising alternative to the available treatments, and is already approved for the treatment of AA. Keywords: alopecia areata, baricitinib, JAK-STAT, JAK inhibitors, pathophysiology, treatment.

2023年3月1日 · Alopecia areata (AA) is an autoimmune disease that causes patchy hair loss on the scalp, face, and body. Baricitinib is a Janus kinase inhibitor that is approved to treat AA in several countries, based on results from two studies, BRAVE-AA1 and BRAVE-AA2.

2024年1月19日 · Baricitinib demonstrated higher response rates and better regrowth outcomes in treating AA compared with the data from clinical trials. The study found that longer treatment duration correlated with improved responses to baricitinib.

The oral Janus kinase inhibitor baricitinib has demonstrated efficacy for adults with severe alopecia areata (≥ 50% scalp hair loss) over 36 weeks. In two phase III trials, efficacy of baricitinib for severe alopecia areata continued to improve over 52 weeks.

Olumiant (baricitinib) is an oral Janus kinase (JAK) inhibitor approved by the U.S. Food and Drug Administration (FDA) for adults with severe alopecia areata (AA) (1). The FDA approved Olumiant for AA in June 2022.

2022年3月26日 · Baricitinib, an oral, selective, reversible inhibitor of Janus kinases 1 and 2, may interrupt cytokine signaling implicated in the pathogenesis of alopecia areata.

2025年2月5日 · Key Takeaways. Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles. Breakdown of immune privilege in hair follicles leads ...

Baricitinib (Olumiant) is labeled for the treatment of severe alopecia areata in adults. 1 It is a Janus kinase inhibitor that interrupts cytokine signaling in the Janus kinase 1 and 2...